Clinical trial
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced…
NCT00004241 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00004241 |
|---|---|
| Title | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma |
| Official title | A Phase I Trial of Weekly 17-Allylamino-17 Demethoxygeldanamycin |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Chondrosarcoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma, Nodal Marginal Zone B-cell Lymphoma and 44 more |
| Intervention type | Drug, Other |
| Interventions | tanespimycin, pharmacological study |
| Enrollment | 60 |
| Start date | Oct 1, 1999 |
| Primary completion | May 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 7, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: